SLC5A2 and diabetes mellitus: Importantly, in studies comprising individuals with normoglycaemia, SGLT-2 inhibitors do not alter fasting plasma glucose levels [55], and so it is not anticipated that SGLT-2 inhibition will increase hypoglycaemia risk in those without diabetes.